02211 UNI HEALTH
- 0.107
- +0.002+1.90%
UNI HEALTH News
Yixintang Pharmaceutical (002727.SZ): Yixintang in Sichuan plans to invest 0.368 billion yuan to construct a large health smart medicine base logistics center project.
On November 26, Yixintang Pharmaceutical (002727.SZ) announced that, according to the company's global strategy and business positioning, in order to improve the logistics distribution capabilities in Sichuan province and meet future development needs, the company has approved its wholly-owned subsidiary, Sichuan Yixintang Pharmaceutical Co., Ltd. (hereinafter referred to as "Sichuan Yixintang"), to invest 0.368 billion yuan in Chengdu, Sichuan province to construct a large health smart medical logistics center project. The construction of the new logistics center is intended to meet the business development needs of the company in the Sichuan-Chongqing region.
Express News | Sichuan Kelun Pharmaceutical established a big health industry company in Zhejiang with a registered capital of 20 million yuan.
Universal Health International Unit Buys Stake in Hollow Capsule Manufacturer
Uni Health (02211.HK) sells capsule production business at a price of 43 million RMB.
Uni Health (02211.HK) announced the complete sale of capsule production business to an independent third party - 43.78% equity of Jilin Jintiandi Uni Health Group, for a cash consideration of RMB 43 million. The net proceeds will be used for general operating funds.
Uni health (02211.HK) intends to sell a 43.78% stake in Jilin Jintian Uni Health Group for 43 million yuan.
On November 19, 2023, uni health (02211.HK) announced that on November 19, 2024, the seller (Heilongjiang Jintian Aixin Pharmaceutical Distribution Co., Ltd.) (an indirectly wholly-owned subsidiary of the company) entered into an equity transfer agreement with the buyer (Huang Yanling), according to which the seller conditionally agreed to sell, and the buyer conditionally agreed to acquire 43.78% of the equity of the target company Jilin Jintian Uni Health Group Capsule Co., Ltd., for a consideration of 43 million yuan, but it is subject to the terms of the equity transfer agreement. After the completion of the sale, the company will no longer hold any equity in the target company.
Guizhou Yibai Pharmaceutical (600594.SH): Currently, the company's major health products focus on throat lozenges, instant drinks, solid beverages, etc.
Gelonghui November 11th | Guizhou Yibai Pharmaceutical (600594.SH) stated on the investor interaction platform that the company's current anti-tumor products include injection of oxaliplatin, Kansai Di capsules, and Aiyu capsules. Currently, the company's large health products are mainly focused on throat lozenges, instant drinks, solid beverages, etc.
China Life Insurance has reached a strategic cooperation with Zenlin Daikang Health and Jianfa International Travel on cross-border residence and health care.
BOC Hong Kong (02388.HK) and BOC Group Life Insurance jointly participated in the 7th China International Import Expo silver economy theme series activities. At the event, BOC Life Insurance signed a strategic cooperation memorandum of understanding on cross-border residential health care with Zhenlin Health Holdings under Yee Lee Group in Macau, as well as Xiamen Jiande International Travel Agency Group (Jiande Guolv) . BOCC Life CEO Deng Ziping stated that BOCC Life will collaborate with BOC Hong Kong, leveraging the advantages of "banks + insurance", relying on BOC's global, integrated, and scenario-based resources and strengths, to cooperate and build a "comprehensive financial products + multi
Tianjin Ringpu Bio-technology (300119.SZ) plans to acquire 15% equity of Sino-Swiss Huapu to improve its strategic layout in the pet health industry.
Zhītōng Cái Jīn APP News, tianjin ringpu bio-technology (300119.SZ) announced that, in order to continuously improve the company's strategic layout in the pet health sector,...
Express News | Minsheng Health: actively seeking new project opportunities in the big health field that are in line with the company's development global strategy and have rich synergies upstream and downstream.
Express News | Moutai's fund is once again making a move, planning to increase its investment in the healthcare industry by 0.554 billion yuan.
Unihealth International [02211] is now trading at 0.147 Hong Kong dollars, up by 13.95%.
As of 13:21, uni health [02211] reported a price of 0.147 Hong Kong dollars, an increase of 0.018 Hong Kong dollars or 13.95% from the closing price of 0.129 Hong Kong dollars yesterday, with a turnover of 0.1336 million Hong Kong dollars. The highest price today is 0.142 Hong Kong dollars, and the lowest price is 0.117 Hong Kong dollars. Based on the closing price yesterday, the 10-day average price is 0.13 Hong Kong dollars, the 50-day average price is 0.08 Hong Kong dollars, and the current P/E ratio is 184.29 times, with a 14-day relative strength index of 66.67.
UNI HEALTH: 2023/24 ANNUAL REPORT
Express News | Guoshou Da Health Fund Phase I fund has an internal rate of return of 31.69% and a distribution return multiple of 1.53.
Express News | Ping An Health Insurance has launched the industry's first digital weight management program, creating three types of standardized standards for three major health product categories.
Express News | Huatai Health: Huatai Large Health plans to reduce its shareholding by no more than 1%.
Beijing Yuanlong Yato Culture Dissemination (002878.SZ): The service enterprise clients are mainly concentrated in industries such as beauty, fast-moving consumer goods, internet, mobile, banks, insurance, and pharmaceuticals and healthcare.
On October 11th, Beijing Yuanlong Yato Culture Dissemination (002878.SZ) stated on the investor interaction platform that the company's service enterprise clients are mainly concentrated in industries such as beauty, fast-moving consumer goods, internet plus-related, mobile, banks, insurance, pharmaceuticals, and health. With the national policy vigorously promoting consumer spending, the improvement in end consumer purchasing power will directly drive clients' marketing demands, benefiting the expansion of the company's marketing business sector in terms of business scale and profitability. In addition, the company has established coverage in IP resources, IP content creation and dissemination, IP derivative product design and development, digital cultural and creative product development and operation, as well as B+C channel and IP e-commerce operation.
Where is the intermediate trend of Hong Kong stocks? Real estate, consumer, and pharmaceuticals are expected to become the main themes.
haitong sec released research reports stating that the policy combination is based on the real economy while also taking into account the capital markets, combined with the previous stock market being at a historic low, the conditions for the start of the intermediate market trend are in place.
Ruiang Gene (688217.SH): Zhejiang Health has cumulatively reduced its shareholding by 0.9982%.
RegeneGene (688217.SH) announced on September 27th that it has received a notice from shareholder Zhejiang Da Health regarding the expiration of the period for the shareholding reduction plan of Shanghai RegeneGene Technology Co., Ltd., as of September 27, 2024, Zhejiang Da Health has reduced its holdings of the company's shares by 557,558 shares through centralized bidding trading, accounting for 0.9982% of the total share capital. The time range for this shareholding reduction plan has expired.
Dongfang Ocean (002086.SZ) plans to collaborate with partners to build a product distribution platform and terminal intensification platform to improve the post-sales system of the health industry.
Dongfang Ocean (002086.SZ) announced that its wholly-owned subsidiary Dongfang Ocean Life Technology Co., Ltd. ("Dongfang...
Universal Health International Swings to Profit in Fiscal 2024
Analysis
Price Target
No Data
No Data